Compare · CELL vs DFTX
CELL vs DFTX
Side-by-side comparison of PhenomeX Inc. (CELL) and Definium Therapeutics Inc. (DFTX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CELL and DFTX operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
- DFTX carries a market cap of $2.57B.
- DFTX has hit the wire 3 times in the past 4 weeks while CELL has been quiet.
- DFTX has more recent analyst coverage (4 ratings vs 0 for CELL).
- Company
- PhenomeX Inc.
- Definium Therapeutics Inc.
- Price
- $1.00+0.14%
- $23.02-2.29%
- Market cap
- -
- $2.57B
- 1M return
- -
- -0.95%
- 1Y return
- -
- +196.46%
- Industry
- Medicinal Chemicals and Botanical Products
- Medicinal Chemicals and Botanical Products
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2020
- News (4w)
- 0
- 3
- Recent ratings
- 0
- 4
Latest CELL
- PhenomeX Announces Opto® Memory B Discovery Human Workflow on the Beacon® Optofluidic Platform
- PhenomeX Announces The Release Of SpotLight Human Lambda Reagent For The Beacon Platform To Accelerate Cell Line Development Workflows
- PhenomeX Announces the Release of SpotLight™ Human Lambda Reagent for the Beacon® Platform to Accelerate Cell Line Development Workflows
- PhenomeX to Participate in Upcoming Cell Biology Conferences
- PhenomeX Unveils Meteor Chips For Quantitative Bulk Analysis On The IsoSpark Platform To Revolutionize High Throughput Multiplexed Hands-Free Proteomic
- PhenomeX Unveils Meteor™ Chips For Quantitative Bulk Analysis On The IsoSpark™ Platform To Revolutionize High Throughput Multiplexed Hands-Free Proteomics
- PhenomeX Inc. Announces Commencement of Cash Tender Offer by Bruker
- Cathie Wood's Bullish Stance on Flying Cars: Ark Buys $3.9M Worth of Archer Aviation Shares
- Lifshitz Law PLLC Announces Investigations of TMBR, PR, ESTE, and CELL
- Benzinga's Top Ratings Upgrades, Downgrades For August 23, 2023
Latest DFTX
- Definium Therapeutics Announces New Employee Inducement Grants
- Definium Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference
- Definium Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Definium Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Definium Therapeutics Announces First Patient Dosed in Ascend, the Second Phase 3 Pivotal Study of DT120 ODT in Major Depressive Disorder
- Definium Therapeutics Announces New Employee Inducement Grants
- SEC Form 10-Q filed by Definium Therapeutics Inc.
- Definium Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Definium Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights
- Definium Therapeutics to Report First Quarter 2026 Financial Results on May 7, 2026